2016
N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment
2005
Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome
Bloch MH, Leckman JF, Zhu H, Peterson BS. Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome. Neurology 2005, 65: 1253-1258. PMID: 16247053, PMCID: PMC2367161, DOI: 10.1212/01.wnl.0000180957.98702.69.Peer-Reviewed Original ResearchConceptsSeverity of ticsBasal ganglia volumesCaudate nucleus volumeTourette syndromeObsessive-compulsive symptomsGanglia volumesEarly adulthoodObsessive-compulsive disorderTic symptomsCaudate nucleusCaudate volumeCross-sectional imaging studiesThalamo-cortical circuitsNucleus volumeSeverity of symptomsAge 16 yearsProspective longitudinal studyAge 14 yearsClinical statusClinical assessmentClinical measuresMorphologic disturbancesMRI scansSymptomsImaging studies